Fintel reports that on May 26, 2023, Citigroup maintained coverage of Arcus Biosciences (NYSE:RCUS) with a Buy recommendation.
Analyst Price Forecast Suggests 99.09% Upside
As of May 11, 2023, the average one-year price target for Arcus Biosciences is 43.86. The forecasts range from a low of 22.22 to a high of $73.50. The average price target represents an increase of 99.09% from its latest reported closing price of 22.03.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arcus Biosciences is 104MM, a decrease of 12.66%. The projected annual non-GAAP EPS is -4.75.
What is the Fund Sentiment?
There are 469 funds or institutions reporting positions in Arcus Biosciences. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to RCUS is 0.16%, a decrease of 17.21%. Total shares owned by institutions increased in the last three months by 4.65% to 61,144K shares. The put/call ratio of RCUS is 0.41, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR – iShares Core S&P Small-Cap ETF holds 3,803K shares representing 5.20% ownership of the company. In it’s prior filing, the firm reported owning 3,877K shares, representing a decrease of 1.93%. The firm decreased its portfolio allocation in RCUS by 15.93% over the last quarter.
FBIOX – Biotechnology Portfolio holds 3,193K shares representing 4.37% ownership of the company. No change in the last quarter.
Octagon Capital Advisors holds 2,172K shares representing 2.97% ownership of the company. In it’s prior filing, the firm reported owning 2,483K shares, representing a decrease of 14.30%. The firm decreased its portfolio allocation in RCUS by 28.70% over the last quarter.
XBI – SPDR(R) S&P(R) Biotech ETF holds 1,882K shares representing 2.57% ownership of the company. In it’s prior filing, the firm reported owning 2,506K shares, representing a decrease of 33.16%. The firm decreased its portfolio allocation in RCUS by 49.48% over the last quarter.
Citadel Advisors holds 1,766K shares representing 2.42% ownership of the company. In it’s prior filing, the firm reported owning 643K shares, representing an increase of 63.58%. The firm increased its portfolio allocation in RCUS by 97.83% over the last quarter.
Arcus Biosciences Background Information
(This description is provided by the company.)
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
